In recent years, Saudi Arabia has recognized the pivotal role of digital health solutions in modern healthcare. Central to this digital transformation is the regulation of Software as a Medical Device (SaMD). The Saudi Food and Drug Authority (SFDA) has established comprehensive guidelines, such as MDS-G23  Guidance on Software as a Medical Device, to ensure that SaMD products meet stringent safety and efficacy standards before entering the Saudi market. 

Understanding SaMD 

Software as a Medical Device (SaMD) refers to software intended for medical purposes that operates independently of any hardware medical device. It can function on general-purpose platforms like smartphones, computers, or tablets and may be used alone or in combination with other medical devices. Notably, SaMD includes in-vitro diagnostic (IVD) devices but excludes software solely intended to drive hardware medical devices. Mobile applications meeting these criteria are also considered SaMD.  

SFDA’s Regulatory Framework for SaMD 

The SFDA has adopted the International Medical Device Regulators Forum (IMDRF) guidelines to regulate SaMD, ensuring patient safety while fostering innovation. This framework emphasizes a risk-based approach, categorizing SaMD based on the significance of the information provided and the healthcare situation’s criticality.  

Key Factors in SaMD Categorization 

Significance of Information Provided by SaMD: 

• To Treat or Diagnose: SaMD that provides information prompting immediate actions for treatment or diagnosis. 

• To Drive Clinical Management: SaMD that aids in enhancing the safe and effective use of medical interventions. 

• To Inform Clinical Management: SaMD that offers information without triggering immediate action, supporting long-term health management. 

State of the Healthcare Situation or Condition: 

• Critical Situation: Life-threatening conditions requiring immediate intervention. 

• Serious Situation: Conditions where timely treatment is essential to prevent significant health deterioration. 

• Non-Serious Situation: Situations where delayed intervention would not result in serious consequences. 

These factors guide the categorization of SaMD into different risk classes, determining the level of regulatory scrutiny required.  

SaMD Categories 

Criteria for Category IV   

• SaMD that provides information used for treating or diagnosing a disease or condition in a critical situation or condition falls under Category IV. 

Criteria for Category III 

• SaMD that provides information to treat or diagnose a disease or conditions in a serious situation or condition is a Category III and is considered to be of high impact.  

• SaMD that provides information to drive clinical management of a disease or conditions in a critical situation or condition is a Category III and is considered to be of high impact. 

Criteria for Category II  

• SaMD that provides information to treat or diagnose a disease or conditions in a nonserious situation or condition is a Category II and is considered to be of medium impact. 

• SaMD that provides information to drive clinical management of a disease or conditions in a serious situation or condition is a Category II and is considered to be of medium impact.  

• SaMD that provides information to inform clinical management for a disease or conditions in a critical situation or condition is a Category II and is considered to be of medium impact. 

Criteria for Category I 

• SaMD that provides information to drive clinical management of a disease or conditions in a non-serious situation or condition is a Category I and is considered to be of low impact.  

• SaMD that provides information to inform clinical management for a disease or conditions in a serious situation or condition is a Category I and is considered to be of low impact.  

• SaMD that provides information to inform clinical management for a disease or conditions in a non-serious situation or condition is a Category I and is considered to be of low impact. 

SaMD Registration Process in Saudi Arabia 

To market SaMD in Saudi Arabia, manufacturers must obtain approval from the Saudi Food and Drug Authority (SFDA). The registration process involves several critical steps: 

1. Technical File Preparation: 

Develop a comprehensive technical file detailing the SaMD’s design, development, risk management, and clinical evaluation. This file should demonstrate the product’s safety, performance, and compliance with applicable standards.  

2. Appointment of an Authorized Representative: 

Manufacturers without a physical presence in Saudi Arabia must appoint a Saudi-authorized representative. This representative acts as a liaison between the manufacturer and the Saudi Food and Drug Authority (SFDA), facilitating communication and ensuring compliance with local regulations.  

3. Submission of the Medical Device Marketing Authorization (MDMA) Application: 

The authorized representative submits the MDMA application to the SFDA via the GHAD system. This application includes the technical file and other required documentation.  

4. SFDA Review and Approval: 

The SFDA reviews the submitted application to ensure compliance with regulatory requirements. Upon satisfactory evaluation, the SFDA grants the MDMA certificate, authorizing the SaMD’s marketing in Saudi Arabia.  

Post-Market Obligations 

After obtaining the MDMA certificate, manufacturers and their authorized representatives must adhere to post-market surveillance requirements: 

• Incident Reporting: Report any adverse events or malfunctions associated with the SaMD to the SFDA promptly 

• Periodic Safety Updates: Provide regular updates on the SaMD’s safety and performance, as required by the SFDA.  

• Compliance with Advertising Regulations: Ensure all promotional materials and activities comply with SFDA guidelines to prevent misleading information.  

Conclusion 

Saudi Arabia regulates Software as a Medical Device by integrating digital health solutions into its healthcare system. By aligning with international guidelines and implementing a robust regulatory framework, the SFDA ensures that SaMD products entering the Saudi market are safe, effective, and contribute positively to patient care. Manufacturers aiming to introduce SaMD in Saudi Arabia must diligently adhere to these regulations to ensure compliance and successful market entry. 

OMC specializes in guiding businesses through the complexities of SaMD registration, helping them achieve compliance efficiently.